The hereditary genetic testing market size has grown rapidly in recent years. It will grow from $23.88 billion in 2025 to $26.56 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing prevalence of hereditary disorders, growing clinical adoption of molecular diagnostics, expansion of diagnostic laboratories, rising awareness of genetic diseases, availability of basic genetic testing technologies.
The hereditary genetic testing market size is expected to see rapid growth in the next few years. It will grow to $40.12 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to advancements in next-generation sequencing technologies, growing demand for personalized medicine, expansion of pharmacogenomic applications, increasing healthcare spending on preventive care, wider integration of genetic counseling services. Major trends in the forecast period include rising adoption of preventive and predictive genetic testing, increasing demand for early cancer risk assessment, growth of direct-to-consumer genetic testing services, expansion of prenatal and newborn genetic screening, rising awareness of inherited cardiovascular and rare diseases.
The increasing prevalence of cancer is increasingly supporting the expansion of the hereditary genetic testing market going forward. Cancer refers to a group of diseases characterized by uncontrolled cell growth with the potential to invade or spread to other parts of the body. The growing prevalence of cancer is influenced by aging populations, lifestyle changes, environmental exposures, genetic predispositions, and improved diagnostic capabilities. Hereditary genetic testing helps identify inherited genetic mutations linked to increased cancer risk, enabling early surveillance and preventive strategies. For example, in August 2024, according to Macmillan Cancer Support, a UK-based organization, more than 3 million people in the UK were living with cancer in 2024, with projections indicating growth to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. As a result, the increasing cancer burden is contributing to the expansion of the hereditary genetic testing market.
Leading companies operating in the hereditary genetic testing market are focusing on developing advanced genomic solutions, such as multi-cancer multigene panels, to support early detection and personalized treatment strategies. Multi-cancer multigene panels analyze multiple genes simultaneously to identify mutations linked to different cancers, aiding risk assessment and tailored care. For example, in February 2024, Exact Sciences Corporation, a US-based provider of cancer screening and diagnostic tests, launched the Riskguard hereditary cancer test. This test delivers personalized insights into gene-specific and familial cancer risks using a blood or saliva sample, supporting informed screening decisions, treatment planning, and family risk evaluation.
In August 2024, Laboratory Corporation of America Holdings (Labcorp), a US-based laboratory services company, acquired selected assets of Invitae Corporation for an undisclosed amount. With this acquisition, Labcorp aims to expand its specialty testing capabilities and strengthen its use of genetic data to improve clinical trials and treatment approaches in oncology and select rare diseases. Invitae Corporation is a US-based provider of medical genetics services, including genetic testing solutions for oncology and rare diseases.
Major companies operating in the hereditary genetic testing market are F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Hologic Inc., Exact Sciences Corporation, Fulgent Genetics Inc., BioReference Laboratories Inc., BGI Group, Invitae Corporation, Color Health Inc., MedGenome Inc., Devyser AB, Mapmygenome India Ltd., Igenomix S.L.P., Myriad Genetics Inc., Natera Inc., Ambry Genetics Corporation, GeneDx LLC, Centogene N.V., CooperSurgical Inc., Sema4.
North America was the largest region in the hereditary genetic testing market in 2025 and it is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hereditary genetic testing market by increasing costs for imported laboratory instruments, reagents, and sequencing equipment, impacting overall testing affordability. Molecular testing and pharmacogenomic testing segments are most affected, particularly in regions such as Asia-Pacific and Latin America that rely heavily on imported diagnostic technologies. These cost pressures have slowed adoption in price-sensitive markets. However, tariffs have also encouraged domestic manufacturing of testing kits and reagents, fostering local innovation and strengthening regional diagnostic capabilities.
The hereditary genetic testing market research report is one of a series of new reports that provides hereditary genetic testing market statistics, including hereditary genetic testing industry global market size, regional shares, competitors with a hereditary genetic testing market share, detailed hereditary genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary genetic testing industry. This hereditary genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hereditary genetic testing analyzes DNA to detect inherited gene mutations that may increase the risk of disease. It helps identify genetic conditions that may be passed from parents to children, including cancers, heart diseases, and rare inherited disorders.
The primary types of hereditary genetic testing include predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others. Predictive and presymptomatic testing helps identify individuals with a genetic likelihood of developing specific diseases before clinical symptoms appear. The technologies used include cytogenetic testing, biochemical testing, and molecular testing. Clinical applications include cancer genetic testing, cardiovascular genetic testing, neurological genetic testing, and rare disease genetic testing. The end users consist of hospitals and clinics, diagnostic laboratories, research institutes, and direct-to-consumer (DTC) genetic testing providers.
The hereditary genetic testing market includes revenues earned by entities by providing services such as carrier screening, prenatal testing, and newborn screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hereditary genetic testing market size is expected to see rapid growth in the next few years. It will grow to $40.12 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to advancements in next-generation sequencing technologies, growing demand for personalized medicine, expansion of pharmacogenomic applications, increasing healthcare spending on preventive care, wider integration of genetic counseling services. Major trends in the forecast period include rising adoption of preventive and predictive genetic testing, increasing demand for early cancer risk assessment, growth of direct-to-consumer genetic testing services, expansion of prenatal and newborn genetic screening, rising awareness of inherited cardiovascular and rare diseases.
The increasing prevalence of cancer is increasingly supporting the expansion of the hereditary genetic testing market going forward. Cancer refers to a group of diseases characterized by uncontrolled cell growth with the potential to invade or spread to other parts of the body. The growing prevalence of cancer is influenced by aging populations, lifestyle changes, environmental exposures, genetic predispositions, and improved diagnostic capabilities. Hereditary genetic testing helps identify inherited genetic mutations linked to increased cancer risk, enabling early surveillance and preventive strategies. For example, in August 2024, according to Macmillan Cancer Support, a UK-based organization, more than 3 million people in the UK were living with cancer in 2024, with projections indicating growth to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. As a result, the increasing cancer burden is contributing to the expansion of the hereditary genetic testing market.
Leading companies operating in the hereditary genetic testing market are focusing on developing advanced genomic solutions, such as multi-cancer multigene panels, to support early detection and personalized treatment strategies. Multi-cancer multigene panels analyze multiple genes simultaneously to identify mutations linked to different cancers, aiding risk assessment and tailored care. For example, in February 2024, Exact Sciences Corporation, a US-based provider of cancer screening and diagnostic tests, launched the Riskguard hereditary cancer test. This test delivers personalized insights into gene-specific and familial cancer risks using a blood or saliva sample, supporting informed screening decisions, treatment planning, and family risk evaluation.
In August 2024, Laboratory Corporation of America Holdings (Labcorp), a US-based laboratory services company, acquired selected assets of Invitae Corporation for an undisclosed amount. With this acquisition, Labcorp aims to expand its specialty testing capabilities and strengthen its use of genetic data to improve clinical trials and treatment approaches in oncology and select rare diseases. Invitae Corporation is a US-based provider of medical genetics services, including genetic testing solutions for oncology and rare diseases.
Major companies operating in the hereditary genetic testing market are F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Hologic Inc., Exact Sciences Corporation, Fulgent Genetics Inc., BioReference Laboratories Inc., BGI Group, Invitae Corporation, Color Health Inc., MedGenome Inc., Devyser AB, Mapmygenome India Ltd., Igenomix S.L.P., Myriad Genetics Inc., Natera Inc., Ambry Genetics Corporation, GeneDx LLC, Centogene N.V., CooperSurgical Inc., Sema4.
North America was the largest region in the hereditary genetic testing market in 2025 and it is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the hereditary genetic testing market by increasing costs for imported laboratory instruments, reagents, and sequencing equipment, impacting overall testing affordability. Molecular testing and pharmacogenomic testing segments are most affected, particularly in regions such as Asia-Pacific and Latin America that rely heavily on imported diagnostic technologies. These cost pressures have slowed adoption in price-sensitive markets. However, tariffs have also encouraged domestic manufacturing of testing kits and reagents, fostering local innovation and strengthening regional diagnostic capabilities.
The hereditary genetic testing market research report is one of a series of new reports that provides hereditary genetic testing market statistics, including hereditary genetic testing industry global market size, regional shares, competitors with a hereditary genetic testing market share, detailed hereditary genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary genetic testing industry. This hereditary genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hereditary genetic testing analyzes DNA to detect inherited gene mutations that may increase the risk of disease. It helps identify genetic conditions that may be passed from parents to children, including cancers, heart diseases, and rare inherited disorders.
The primary types of hereditary genetic testing include predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others. Predictive and presymptomatic testing helps identify individuals with a genetic likelihood of developing specific diseases before clinical symptoms appear. The technologies used include cytogenetic testing, biochemical testing, and molecular testing. Clinical applications include cancer genetic testing, cardiovascular genetic testing, neurological genetic testing, and rare disease genetic testing. The end users consist of hospitals and clinics, diagnostic laboratories, research institutes, and direct-to-consumer (DTC) genetic testing providers.
The hereditary genetic testing market includes revenues earned by entities by providing services such as carrier screening, prenatal testing, and newborn screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hereditary Genetic Testing Market Characteristics
3. Hereditary Genetic Testing Market Supply Chain Analysis
4. Global Hereditary Genetic Testing Market Trends and Strategies
5. Hereditary Genetic Testing Market Analysis of End Use Industries
7. Global Hereditary Genetic Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hereditary Genetic Testing Total Addressable Market (TAM) Analysis for the Market
9. Hereditary Genetic Testing Market Segmentation
10. Hereditary Genetic Testing Market Regional and Country Analysis
11. Asia-Pacific Hereditary Genetic Testing Market
12. China Hereditary Genetic Testing Market
13. India Hereditary Genetic Testing Market
14. Japan Hereditary Genetic Testing Market
15. Australia Hereditary Genetic Testing Market
16. Indonesia Hereditary Genetic Testing Market
17. South Korea Hereditary Genetic Testing Market
18. Taiwan Hereditary Genetic Testing Market
19. South East Asia Hereditary Genetic Testing Market
20. Western Europe Hereditary Genetic Testing Market
21. UK Hereditary Genetic Testing Market
22. Germany Hereditary Genetic Testing Market
23. France Hereditary Genetic Testing Market
24. Italy Hereditary Genetic Testing Market
25. Spain Hereditary Genetic Testing Market
26. Eastern Europe Hereditary Genetic Testing Market
27. Russia Hereditary Genetic Testing Market
28. North America Hereditary Genetic Testing Market
29. USA Hereditary Genetic Testing Market
30. Canada Hereditary Genetic Testing Market
31. South America Hereditary Genetic Testing Market
32. Brazil Hereditary Genetic Testing Market
33. Middle East Hereditary Genetic Testing Market
34. Africa Hereditary Genetic Testing Market
36. Hereditary Genetic Testing Market Competitive Landscape and Company Profiles
37. Hereditary Genetic Testing Market Other Major and Innovative Companies
40. Hereditary Genetic Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Hereditary Genetic Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hereditary genetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hereditary genetic testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hereditary genetic testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Predictive And Presymptomatic Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Types2) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing
3) By Clinical Application: Cancer Genetic Testing; Cardiovascular Genetic Testing; Neurological Genetic Testing; Rare Diseases Genetic Testing
4) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Direct To Consumer (DTC) Genetic Testing Companies
Subsegments:
1) By Predictive And Presymptomatic Testing: Genetic Testing For Disease Risk Prediction; Testing For Inherited Cancer Risks; Cardiovascular Disease Risk Testing; Neurodegenerative Disease Risk Testing2) By Carrier Testing: Testing For Inherited Genetic Disorders; Genetic Screening For Autosomal Recessive Diseases; Testing For Carrier Status Of Inherited Conditions
3) By Prenatal and Newborn Testing: Non-Invasive Prenatal Testing (NIPT); Amniocentesis and Chorionic Villus Sampling (CVS); Newborn Screening For Genetic Disorders; Preconception Genetic Screening
4) By Diagnostic Testing: Genetic Testing For Confirming Suspected Genetic Disorders; Testing For Inherited Syndromes And Congenital Diseases; Diagnostic Testing For Cancer And Tumor Profiling
5) By Pharmacogenomic Testing: Genetic Testing For Drug Response And Efficacy; Testing For Drug Sensitivities And Side Effects; Personalized Medicine And Treatment Optimization
6) By Other Types: Genetic Testing For Wellness And Lifestyle; Genetic Testing For Ancestry And Genealogy; Research-Oriented Genetic Testing
Companies Mentioned: F. Hoffmann‑La Roche Ltd.; Abbott Laboratories; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Eurofins Scientific SE; Hologic Inc.; Exact Sciences Corporation; Fulgent Genetics Inc.; BioReference Laboratories Inc.; BGI Group; Invitae Corporation; Color Health Inc.; MedGenome Inc.; Devyser AB; Mapmygenome India Ltd.; Igenomix S.L.P.; Myriad Genetics Inc.; Natera Inc.; Ambry Genetics Corporation; GeneDx LLC; Centogene N.V.; CooperSurgical Inc.; Sema4
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hereditary Genetic Testing market report include:- F. Hoffmann‑La Roche Ltd.
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Eurofins Scientific SE
- Hologic Inc.
- Exact Sciences Corporation
- Fulgent Genetics Inc.
- BioReference Laboratories Inc.
- BGI Group
- Invitae Corporation
- Color Health Inc.
- MedGenome Inc.
- Devyser AB
- Mapmygenome India Ltd.
- Igenomix S.L.P.
- Myriad Genetics Inc.
- Natera Inc.
- Ambry Genetics Corporation
- GeneDx LLC
- Centogene N.V.
- CooperSurgical Inc.
- Sema4
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 26.56 Billion |
| Forecasted Market Value ( USD | $ 40.12 Billion |
| Compound Annual Growth Rate | 10.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
